YD Bio Limited Ordinary Shares (YDES)

TW — Healthcare Sector
Peers: VIR  MRVI  TBPH  GERN  LENZ  DAWN  GLUE  PRME  BTX  TYRA 

Automate Your Wheel Strategy on YDES

With Tiblio's Option Bot, you can configure your own wheel strategy including YDES - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol YDES
  • Rev/Share 0.0
  • Book/Share -4.7076
  • PB -1.8417
  • Debt/Equity 0.0
  • CurrentRatio 0.0171
  • ROIC 0.1668

 

  • MktCap 611420183.0
  • FreeCF/Share -0.3449
  • PFCF -519.9947
  • PE -9.9373
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 0.283

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES
YDES
Published: October 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Taipei, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today rang the Opening Bell at Nasdaq MarketSite in New York to celebrate its public listing on the Nasdaq Global Market. This milestone strengthens YD Bio's capital base, elevates its global profile and accelerates the commercialization of its next-generation diagnostic and regenerative medicine platforms.

Read More
image for news YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

About YD Bio Limited Ordinary Shares (YDES)

  • IPO Date 2025-08-29
  • Website https://www.ydesgroup.com
  • Industry Biotechnology
  • CEO Ethan Shen
  • Employees 4

Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.